# Counter-Analysis: IMB.L (Imperial Brands PLC)

## Fecha: 2026-02-10

## !! CRITICAL ALERT !!

**Two material risks discovered by risk-sentinel on 2026-02-09 are CONFIRMED and UNDERESTIMATED by the thesis. Combined with a FACTUAL ERROR in the thesis (dividend was CUT 33% in 2020, thesis claims "never cut"), and cumulative regulatory acceleration across 3 of 5 priority markets, the counter-case has strengthened materially since the Feb-08 adversarial review.**

---

## Resumen Ejecutivo

The IMB.L bull thesis rests on three pillars: (1) pricing power forever offsets volume decline, (2) 10%+ FCF yield provides income regardless of capital gains, and (3) the stock is cheap because ESG exclusion creates opportunity. This counter-analysis finds all three pillars are under attack from accelerating regulatory change, a confirmed $251.5M-$400M legal settlement, and a UK vaping excise duty that undermines NGP growth. The thesis contains a factual error (claims dividend "never cut" when it was slashed 33% in 2020), overstates quality (9.5/10 vs tool 54/100), and uses a DDM with growth in perpetuity for a business facing legislated demand destruction. The stock at 3,277 GBp has approximately 0-4% MoS vs the independent valuation of 3,409 GBp -- inadequate for a Tier C company with this risk profile.

---

## Asunciones Clave Desafiadas

### 1. "Pricing Power Offsets Volume Decline Indefinitely"

- **Thesis claim:** Revenue grows 3-4% because pricing (+5-6%) more than offsets volume decline (-3%).
- **Evidence in contra:**
  - FY25 *reported* revenue declined -0.7% YoY (GBP 32.17B). The thesis uses constant-currency net revenue (+4.1%) which flatters the picture. Currency headwinds are real and persistent.
  - Pricing power is showing strain. Industry data shows the "rapid growth of the discount segment suggests there is a ceiling to how much the premium consumer can be squeezed." Manufacturers retain pricing power "but not as strong as before."
  - Australia menthol ban (April 2025) + individual stick health warnings + plain packaging tightening directly attacks consumption in a priority market. These are NEW regulatory tools beyond traditional excise increases.
  - UK generational ban (Jan 2027) + vaping excise duty (Oct 2026) creates a TWO-FRONT assault on both combustibles AND NGP in Imperial's HOME market.
  - The critical question is not "does pricing power work today?" but "at what volume decline rate does pricing fail to compensate?" If volume decline accelerates from -3% to -5% (plausible with generational bans + menthol bans), the math breaks: -5% volume + 6% price = +1% net, minus inflation and regulatory costs = potential real decline.
- **Severity:** HIGH (7/10) -- The assumption has been correct for 50+ years but the regulatory environment is qualitatively different now with generational bans.
- **Resolution sugerida:** Model a two-phase revenue scenario: Phase 1 (next 5 years) assumes current pricing holds; Phase 2 (years 6-15) assumes accelerating volume decline as generational bans propagate. The DDM with 4.5% growth in perpetuity is structurally wrong for a declining industry with legislated demand destruction.

### 2. "The $400M Florida Settlement Is a One-Time Event"

- **Thesis claim:** Not mentioned at all. The original thesis does not reference the ITG Brands / Reynolds American Florida settlement.
- **Evidence in contra:**
  - **CONFIRMED:** Delaware Chancery Court ordered ITG Brands (Imperial's US subsidiary) to pay $251.5 million to Reynolds American for Florida tobacco settlement obligations. Vice Chancellor Lori Will rejected ITG's attempt to reduce the amount. The case arose from Reynolds' June 2015 sale of Kool, Maverick, Salem, and Winston brands.
  - **Fitch projects $400M total payment in 2026**, treating it as cash-material to the credit profile.
  - Imperial's FY25 FCF was GBP 2.7B (~$3.4B). A $400M payment = **11.8% of annual FCF** consumed in a single year.
  - This is NOT just a "one-time" payment. The underlying Florida tobacco settlement requires ANNUAL payments. The $251.5M reflects accumulated past-due amounts, but ongoing annual obligations continue. The dispute was about WHO pays (ITG vs Reynolds) for brands sold in 2015.
  - ITG has said it plans to appeal, but Delaware Supreme Court proceedings suggest appeals are largely exhausted. Bloomberg reported Reynolds and ITG "sparring" in appellate proceedings, indicating continued legal costs.
  - Impact chain: $400M payment in 2026 reduces FCF available for buyback by ~27% (vs GBP 1.45B planned buyback). Either the buyback shrinks, leverage increases, or dividend growth slows.
- **Severity:** HIGH (8/10) -- Confirmed, material ($400M = ~11-13% of FCF), and the thesis completely ignores it.
- **Resolution sugerida:** Investment committee must model FY2026 FCF after the $400M settlement. If FCF drops from ~GBP 2.7B to ~GBP 2.4B (post-settlement), the FCF yield drops from 10.3% to ~9.1% at current price. The buyback capacity and dividend growth trajectory need re-evaluation.

### 3. "UK Generational Ban Is 15+ Years Away From Impact"

- **Thesis claim:** Risk assessment says "Short-term: minimal impact" and "Impact is very slow (decades)."
- **Evidence in contra:**
  - The bill is in FINAL STAGES in the House of Lords (committee stage completed Nov 2025, last updated Feb 6, 2026). Age restrictions take effect **January 1, 2027** -- less than 11 months away.
  - **The IMMEDIATE impact is not on tobacco volumes but on investor sentiment and terminal value.** When a government legislates the extinction of your product over 30-50 years, rational investors reduce the terminal value to zero. This is what the DDM misses entirely.
  - UK represents **11.7% of net sales** (confirmed from annual report data) and Imperial has **~42% UK tobacco market share** (largest player). The UK is not a peripheral market -- it is HOME.
  - **Vaping excise duty of GBP 2.20 per 10ml** takes effect October 2026. This directly attacks Imperial's NGP growth story in the UK. Blu vapes will become ~30-40% more expensive for consumers. This is the first time UK has taxed vaping products, creating a NEW headwind on the business segment the thesis presents as "free optionality."
  - **The Maldives has already implemented a generational ban** (born after 2007, effective Nov 2025) -- the world's first. The UK will be the first G7 economy. This establishes precedent.
  - **EU TPD3 revision** is now pushed to mid-2026, and includes potential generational ban discussions. If the EU follows the UK model, Imperial's exposure rises from 11.7% (UK only) to **36%+ of net sales** (UK 11.7% + Germany 13.9% + France 10.4%).
  - Australia (a priority market) already implemented menthol ban + individual stick health warnings + new packaging rules in 2025. While not a generational ban, it demonstrates the regulatory escalation trajectory.
- **Severity:** CRITICAL (9/10) -- The contagion risk is real and accelerating. Three of five priority markets (UK, Australia, and potentially Germany via EU) face ESCALATING regulation. This is not a 15-year problem; it is a terminal value problem TODAY.
- **Resolution sugerida:** The DDM must be restructured as a two-stage model. Stage 1 (years 1-10): 3-4% dividend growth. Stage 2 (terminal): 0% to NEGATIVE growth, reflecting the legislated decline of the addressable market. A perpetuity DDM with 4.5% growth is intellectually dishonest for a product being legislated out of existence.

### 4. "Dividend Is Safe and Progressive -- Never Cut"

- **Thesis claim:** "Dividend 10+ years uncut" (Section 5, Quality Score). The thesis gives full marks (1/1) for this criterion.
- **Evidence in contra:**
  - **FACTUAL ERROR IN THESIS:** Imperial Brands CUT its dividend by 33% in 2020.
    - FY2019: 206.57p per share
    - FY2020: 137.71p per share (rebased)
    - This is a -33.3% cut. The company called it a "rebase" to accelerate debt reduction, but it is unambiguously a dividend cut.
  - The thesis was written in Jan/Feb 2026 and should have known this. The claim "never cut" is factually wrong and calls into question the rigor of the entire quality assessment.
  - Current dividend (FY2025): ~160.32p. This is still **22.4% below the FY2019 level of 206.57p** six years later.
  - The "progressive dividend policy" is progressive from the REBASED level, not from the pre-cut level. DPS growth of 4.5% per year from 137.7p base = it will take until ~FY2029 to recover to 2019 levels.
  - Bear case dividend scenario: If FCF pressure from the $400M settlement + vaping excise costs + accelerating volume decline forces another "rebase," the dividend yield collapses and the entire income thesis fails. This has happened before (2020).
- **Severity:** HIGH (8/10) -- A factual error that inflates the Quality Score and understates dividend risk. The thesis gives 1/1 for dividend safety when the correct score should be 0.5/1 at best (cut within last 6 years).
- **Resolution sugerida:** Correct the thesis. The QS should deduct at least 0.5 points for the 2020 dividend cut. More importantly, stress-test the dividend under a scenario where FY2026 FCF is reduced by $400M (ITG settlement) + GBP 100-200M (vaping excise compliance costs + volume impact). Can the company still grow the dividend 4.5% while maintaining the GBP 1.45B buyback AND servicing GBP 8.4B of net debt?

### 5. "Quality Score 9.5/10 (Tier A)"

- **Thesis claim:** QS 9.5/10, Tier A. Updated note (Session 52) acknowledges QS Tool = 54 (Tier C) and sets "QS Adjusted: 54 (Tier C)."
- **Evidence in contra:**
  - The quality_scorer.py tool calculates QS = 54/100 (Tier C). The risk assessment and valuation report both independently estimate 60-65 (Tier B).
  - The thesis's original 9.5/10 scoring has specific flaws:
    - Full marks for "Dividend 10+ years uncut" -- WRONG (33% cut in 2020)
    - Full marks for "Wide moat" -- Moat is based on addiction, which is a DEPLETING asset in a generational ban environment
    - Full marks for "ROIC < WACC 3 years: NO" -- Tool measures 2.1pp spread, and even independent estimates of 6.7pp spread are modest for a "Tier A" company
    - Uses a simplistic 10-point checklist vs the 100-point framework
  - Under the QS Tool-First rule (Session 52), the QS should be 54 (Tier C) with any adjustments documented. The adversarial review and valuation report converge on ~60-65 (Tier B) when adjusting for tobacco's excise tax distortion of revenue-based metrics.
  - At Tier B-C, the required MoS should be 20-30% (per precedents in decisions_log.yaml). Current MoS of 0-4% is grossly insufficient.
- **Severity:** HIGH (7/10) -- The Session 52 update already corrected this to Tier C, but the implications for position sizing and MoS have not been fully processed. A 5% position in a Tier C company with 0-4% MoS violates every precedent in the decisions log.
- **Resolution sugerida:** Apply the Tier C framework consistently: either the MoS must increase to 20-30% (requiring price to fall to ~2,400-2,700 GBp) or the position should be exited per Principio 9 (Quality Gravitation).

---

## Desafios por Categoria

### Negocio

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 1 | Moat is DEPLETING, not expanding | UK generational ban legislates extinction of addressable market; moat is addiction-based but addressable population shrinks by one birth cohort per year | HIGH |
| 2 | NGP strategy is competitively irrelevant | Imperial NGP = ~4.4% of revenue. PMI IQOS = 38.8%, BAT Vuse = 13.3%. Imperial is the Blackberry of tobacco -- dominant in legacy, irrelevant in future | HIGH |
| 3 | UK vaping excise duty undermines NGP growth in home market | GBP 2.20/10ml duty from Oct 2026. Blu vapes become 30-40% more expensive. First-ever UK vape tax creates new headwind on the ONE growth segment | MODERATE |
| 4 | Pricing power showing strain | Discount segment growing; manufacturers retain pricing power "but not as strong as before"; 60% of retailers report nicotine customer traffic pressured | MODERATE |
| 5 | Australia menthol ban + stick warnings (Apr 2025) | Priority market faces new regulatory tools; menthol ban removes a key product category; individual stick warnings unprecedented outside Canada | MODERATE |

### Valoracion

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 6 | DDM uses perpetuity growth for a declining industry | 4.5% DPS growth forever assumes pricing power forever. Generational bans mean addressable market shrinks to zero over 30-50 years. Terminal value should trend toward zero, not grow at 4.5% | CRITICAL |
| 7 | MoS at current price is 0-4% (essentially zero) | Independent valuation FV 3,409 GBp vs current 3,277 GBp = 4.0% MoS. Bear case FV 2,584 GBp = -21% MoS. This is inadequate for Tier C (need 20-30%) | HIGH |
| 8 | Thesis ignores $400M ITG settlement impact on FV | $400M reduces FY2026 FCF by ~12%. If persistent annual obligations exist, recurring FCF is lower than thesis assumes. This should reduce DCF and FCF-yield based FV by 5-8% | HIGH |
| 9 | WACC likely understated | Thesis uses 7.5%, theoretical WACC 4.7% (absurd with beta 0.139). Alpha Spread calculates 7.17%. With regulatory risk premium, 8-9% is more appropriate. Every 1pp higher WACC reduces DDM FV by ~400p | MODERATE |
| 10 | DCF produces inflated values for declining businesses | Thesis's DCF gives base case 5,038p (64% upside!) -- clearly wrong for a company in secular decline. DCF projects current FCF forward and applies terminal value that assumes perpetual cash flows | MODERATE |

### Riesgos

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 11 | $400M Florida settlement CONFIRMED, not mentioned in thesis | Delaware court ordered $251.5M; Fitch projects $400M in 2026; appeals largely exhausted. Equals 11.8% of annual FCF | HIGH |
| 12 | UK Tobacco & Vapes Bill in final stages, takes effect Jan 2027 | Passed Commons 415-47, Lords committee completed Nov 2025, updated Feb 6, 2026. Near-certain to become law | HIGH |
| 13 | EU TPD3 revision (mid-2026) could include generational ban | If EU follows UK model, 36%+ of Imperial's net sales face legislated demand destruction | HIGH |
| 14 | Dividend was CUT 33% in 2020 -- thesis claims "never cut" | FY2019: 206.57p -> FY2020: 137.71p = -33.3%. Factual error undermines quality assessment | HIGH |
| 15 | Vaping excise duty (Oct 2026) creates new cost headwind for NGP | GBP 2.20/10ml. First-ever UK vape tax. Direct hit to the growth story | MODERATE |
| 16 | Volume decline acceleration risk | If decline moves from -3% to -5% with generational bans, pricing power cannot fully compensate | MODERATE |
| 17 | Debt/Equity 1.82x in a declining industry | GBP 8.4B net debt must be serviced from shrinking volume base. EUR 650M + USD 400M + GBP 188M maturing in 2026 | LOW |

### Timing

| # | Desafio | Evidencia | Severidad |
|---|---------|-----------|-----------|
| 18 | UK vaping excise duty takes effect Oct 2026 | 8 months away. Will create cost inflation for blu products and potentially reduce demand | HIGH |
| 19 | UK generational ban takes effect Jan 2027 | 11 months away. While direct volume impact is minimal initially, the LEGISLATIVE CERTAINTY crushes terminal value | HIGH |
| 20 | ITG settlement payment expected in 2026 | $400M cash outflow in same fiscal year as buyback, dividend growth, and vaping duty compliance | MODERATE |
| 21 | EU TPD3 revision pushed to mid-2026 | Regulatory uncertainty hangs over the stock for the next 4-6 months | MODERATE |
| 22 | H1 FY26 results (May 2026) | First results reflecting post-ban environment in Australia (menthol ban). If Australian volumes crash, it foreshadows UK impact | LOW |

---

## Conflictos con Otros Analisis

### vs Valuation Report (Feb 2026)
- **Agreement:** Both identify QS discrepancy as major issue (thesis 9.5/10 vs tool 54). Both estimate true QS at 60-65 (Tier B).
- **Agreement:** Independent FV of 3,409 GBp vs thesis 3,701 GBp (-7.9%).
- **My concern that valuation report UNDERESTIMATES:** The valuation report uses DDM with 3.5% growth in perpetuity, which is STILL too high for a business facing generational bans. A two-stage DDM (3.5% for 10 years, then 0% or -1% terminal) would produce FV of ~2,800-3,000 GBp, significantly below the 3,409 GBp base case.

### vs Risk Assessment (Feb 2026)
- **Agreement:** Both identify UK generational ban, DDM fragility, and ESG divestment as top risks.
- **Risk assessment MISSED:**
  - The $400M ITG settlement (confirmed by risk-sentinel on Feb 9)
  - The UK vaping excise duty (Oct 2026) impact on NGP
  - The dividend cut history (factual error in thesis)
  - Australia's April 2025 menthol ban + stick warnings
  - The Maldives as first country with operational generational ban

### vs Thesis (Jan-Feb 2026)
- **Thesis claims Tier A; all subsequent analysis finds Tier B-C.** This is the most fundamental conflict.
- **Thesis claims dividend "never cut"; it was cut 33% in 2020.** Factual error.
- **Thesis claims 1/10 value trap score.** I count at least 3-4/10:
  1. Secular industry decline -- YES
  2. Regulatory risk (generational bans, not just traditional regulation) -- effectively YES
  3. Dividend cut recent (2020, within 6 years) -- YES
  4. Arguable: Losing competitive position in NGP vs PMI/BAT -- borderline YES

---

## Veredicto Global

| Metric | Valor |
|--------|-------|
| Total desafios | 22 |
| Desafios HIGH/CRITICAL | 13 of 22 (59%) |
| Desafios no resueltos por thesis | 14 of 22 (64%) |
| Factual errors in thesis | 1 confirmed (dividend "never cut") |
| New risks since last review | 2 (ITG $400M + UK vaping excise duty) |
| Veredicto | **STRONG COUNTER** |

### Interpretacion:

**STRONG COUNTER** -- The thesis has serious problems that have WORSENED since the Feb-08 adversarial review.

1. **The $400M ITG settlement is confirmed, material (12% of FCF), and completely absent from the thesis.** Even if the company can absorb it financially, it reduces FCF available for buybacks and dividend growth in FY2026.

2. **The UK generational ban is near-certain to become law in 2026, with implementation from Jan 2027.** Combined with the UK vaping excise duty from Oct 2026, Imperial faces a two-front regulatory assault in its HOME market within 12 months.

3. **The thesis contains a factual error** (dividend "never cut" when it was slashed 33% in 2020), which inflates the Quality Score and understates dividend risk.

4. **Three of five priority markets face escalating regulation** (UK: generational ban + vaping duty; Australia: menthol ban + stick warnings + packaging; EU/Germany: TPD3 revision pending). The thesis treats these as isolated risks; they are correlated and reinforcing.

5. **The MoS at current price (0-4%) is grossly inadequate** for a Tier C company. Every precedent in decisions_log.yaml shows Tier C positions require 30%+ MoS, and positions with MoS near zero have been exited (SHEL.L at -3.5%, PFE at -3.2%).

---

## Recomendacion al Investment Committee

### PRIMARY QUESTION: Should IMB.L be SOLD?

**Arguments FOR sell:**
- QS 54 (Tier C) with 0-4% MoS -- every precedent says EXIT
- Principio 9 (Quality Gravitation): This is NOT a quality compounder. It is a declining cash cow.
- ROIC spread is 2.1pp (quality_scorer.py) to 6.7pp (Alpha Spread) -- modest at best, not compounding territory
- 8/8 prior positions with ROIC near/below WACC were sold (pattern from decisions_log.yaml)
- $400M FCF hit in 2026 + accelerating regulatory environment
- Dividend was cut 33% in 2020, proving it CAN happen again
- Three of five priority markets face escalating regulatory destruction
- The stock has appreciated from 3,066p entry to 3,277p (+6.9%) -- opportunity to exit with small gain

**Arguments AGAINST sell (intellectual honesty):**
- FCF generation remains strong (GBP 2.7B, 10.3% yield). Even after $400M settlement, FCF yield is ~9%.
- Dividend IS growing (4-5% from rebased level) and payout ratio is conservative (51%)
- The company returns ~11% of market cap annually (dividends + buybacks)
- Forward total return of ~8-10% (yield + DPS growth) is decent, though not exceptional
- Credit ratings (BBB/Baa3, stable outlook) suggest no immediate solvency risk
- The generational ban's volume impact is genuinely slow (affects those born after 2009, not current smokers)
- GBP 3.32B of undrawn facilities provides liquidity buffer

**My assessment:** The SELL arguments are stronger. The stock is approximately fairly valued with ZERO margin of safety in a business with deteriorating long-term fundamentals. The forward return of 8-10% is achievable from income alone, but a Tier A compounder would deliver 15%+ with better quality. The opportunity cost of holding IMB.L when 6 Tier A positions exist in the portfolio is real and quantifiable.

### SPECIFIC ACTIONS the Committee should take before deciding:

1. **Model FY2026 FCF** after the $400M ITG settlement payment. What is the ACTUAL FCF available for buyback + dividend growth? Does the 4.5% DPS growth target survive?

2. **Restructure the DDM** as a two-stage model: 3.5% DPS growth for 10 years, then 0% terminal. What FV does this produce? (My estimate: ~2,800-3,000 GBp, implying the stock is 9-17% OVERVALUED.)

3. **Evaluate the Opportunity Score** vs the best Tier A candidate in pipeline. With IMB.L at QS ~54-65 and MoS 0-4%, virtually ANY Tier A candidate with MoS >15% would have OS > 2.0.

4. **Set a decision deadline:** If the committee decides HOLD, set a kill condition: "If UK Tobacco & Vapes Bill receives Royal Assent AND the stock has not fallen to 2,700 GBp or below, EXIT."

---

## ðŸ”„ META-REFLECTION

### Dudas/Incertidumbres
- The ROIC spread discrepancy is significant. The quality_scorer.py says 2.1pp (which would be near-zero or negative after the $400M settlement year). Alpha Spread says 6.7pp. The truth depends on how capital is measured (with or without tobacco acquisition goodwill from decades ago). I could not resolve this definitively with available data.
- I could not quantify the EXACT annual ongoing obligations from the Florida settlement (the $251.5M/$400M is accumulated back-payments, but there are recurring annual obligations whose size I could not determine).
- The EU TPD3 probability of including a generational ban is genuinely uncertain. I estimate 20-30% within 5 years. This is a guess, not data.
- I may be suffering from recency bias -- the risk-sentinel discoveries (ITG $400M, UK bill progress) are fresh and may be causing me to weight them more heavily than warranted.

### Limitaciones de Este Analisis
- I could not access the full FY2025 Annual Report for detailed geographic revenue breakdown or the specific Florida settlement accounting treatment.
- I could not find analyst consensus models for FY2026 FCF that incorporate the ITG settlement.
- The impact of the UK vaping excise duty on Imperial's NGP margins is unknown -- I used estimates based on retail price impact, not internal margin data.
- I could not find specific data on whether the ITG settlement creates recurring annual obligations or is truly a one-time payment.

### Sugerencias para el Sistema
- The thesis factual error (dividend "never cut") suggests a need for automated fact-checking of thesis claims against historical data. A tool that verifies dividend history, ROIC history, and revenue trends against stated thesis claims would prevent this class of error.
- For industries with legislated demand destruction (tobacco, coal, etc.), the valuation framework should mandate a two-stage or declining-growth model. A perpetuity DDM with positive growth is structurally inappropriate.
- Risk-sentinel should be run BEFORE the initial thesis is written (or at least before investment committee approval), not only as a periodic monitoring tool.

### Preguntas para Orchestrator
1. **With 0-4% MoS on a Tier C position with 13 HIGH/CRITICAL counter-arguments, how does IMB.L "earn its place" under Principio 9?** The 8 prior ROIC-near-WACC exits set a strong precedent for consistency.
2. **Should the $400M ITG settlement trigger a kill condition review?** It reduces FCF by 12% in a single year, which may stress the dividend growth / buyback capacity.
3. **The portfolio has 6 Tier A positions and ~25% cash. Is holding a Tier C tobacco stock the best use of this capital?** Even if IMB.L delivers 8-10% total return, the opportunity cost vs deploying that capital into a Tier A at 15%+ forward return is significant.
4. **Should we set a hard deadline for the UK bill's Royal Assent as a trigger for action?** The bill is in final stages; Royal Assent could come within months.

---

## Sources

- [ITG Owes Reynolds American $251.5 Million -- US News](https://www.usnews.com/news/us/articles/2025-03-03/itg-owes-reynolds-american-251-5-million-for-florida-tobacco-settlement-judge-rules)
- [Imperial Brands PLC Stock News -- Fitch BBB, ITG Settlement](https://ts2.tech/en/imperial-brands-plc-stock-lse-imb-news-and-forecast-dec-20-2025-fitch-bbb-call-buyback-momentum-and-2026-catalysts/)
- [Reynolds, Imperial Brands Unit Spar Over Florida Damages -- Bloomberg Law](https://news.bloomberglaw.com/us-law-week/reynolds-imperial-brands-unit-spar-over-florida-tobacco-damages)
- [UK Tobacco and Vapes Bill -- Parliament.uk](https://bills.parliament.uk/bills/3879)
- [Tobacco and Vapes Bill -- Wikipedia](https://en.wikipedia.org/wiki/Tobacco_and_Vapes_Bill)
- [UK Vaping Products Duty -- GOV.UK](https://www.gov.uk/government/publications/introduction-of-vaping-products-duty-from-1-october-2026/introduction-of-vaping-products-duty-from-1-october-2026)
- [Maldives Generational Ban -- IFL Science](https://www.iflscience.com/worlds-first-generational-tobacco-ban-takes-effect-for-people-born-after-2007-81417)
- [Australia Menthol Ban 2025 -- Cancer Council](https://www.cancer.org.au/media-releases/2025/safeguarding-australia-s-position-as-tobacco-control-leaders-new-smoking-health-warnings-pack-inserts-and-a-ban-on-menthols-from-april-1)
- [TPD3 EU Overhaul -- Tobacco Asia](https://www.tobaccoasia.com/features/tpd-3-eu-set-to-overhaul-tobacco-rules/)
- [Imperial Brands FY25 Results -- PDF](https://www.imperialbrandsplc.com/content/dam/imperialbrands/corporate/documents/investor-hub/results/2025/IMB-FY25-Results-Slides.pdf.downloadasset.pdf)
- [Imperial Brands Dividend History -- DividendMax](https://www.dividendmax.com/united-kingdom/london-stock-exchange/tobacco/imperial-brands-plc/dividends)
- [Fitch Affirms Imperial Brands BBB Stable](https://www.fitchratings.com/research/corporate-finance/fitch-affirms-imperial-brands-at-bbb-outlook-stable-15-04-2025)
- [Moody's Affirms Imperial Brands Baa3](https://ratings.moodys.com/ratings-news/412916)
- [Imperial Brands ROIC -- GuruFocus](https://www.gurufocus.com/term/roic/IMBBY)
- [Imperial Brands WACC -- Alpha Spread](https://www.alphaspread.com/security/lse/imb/discount-rate)
- [Tobacco Pricing Power Under Strain -- Rochester Business Journal](https://rbj.net/2026/02/06/the-curious-economics-of-a-shrinking-smoking-market/)
- [Imperial Brands Dividend Cut 33% -- Proactive Investors](https://www.proactiveinvestors.co.uk/companies/news/919892/imperial-brands-falls-as-dividend-cut-by-a-third-to-speed-debt-reduction-919892.html)
